Literature DB >> 11853105

Dopamine effect on the mitochondria potential in B lymphocytes of schizophrenic patients and normal controls.

Ahmed M Elkashef1, Heba Al-Barazi, Dianne Venable, Ivory Baker, James Hill, Jose Apud, Richard Jed Wyatt.   

Abstract

Brain metabolic abnormalities and aberrant dopamine (DA) metabolism have been reported in patients with schizophrenia. The authors hypothesized that mitochondria is a primary target of damage by increased free radical generation secondary to increased DA metabolism by monoamine oxidase (MAO). Epstein-Barr virus (EBV)-transformed human B-lymphocytes cell lines derived from patients with schizophrenia and normal controls were incubated in the absence or presence of DA, hydrogen peroxide (H2O2), or rotenone (Rot). The cells were then stained with rhodamine 123 (Rh 123) and analyzed for uptake using flow cytometry. Compared with untreated cells, DA significantly decreased Rh 123 uptake by the mitochondria. This effect was similar to the control cells treated with H2O2 or Rot. Nevertheless, there were no differences in Rh 123 uptake between the cells of schizophrenic patients and normal controls. This study shows that DA can impair the mitochondria membrane potential but that mechanism may not be evident in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11853105     DOI: 10.1016/s0278-5846(01)00239-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  2 in total

1.  Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study.

Authors:  Hui-chun Li; Qiao-zhen Chen; Ying Ma; Jun-fu Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2006-12       Impact factor: 3.066

Review 2.  Close encounters of the monoamine kind: immune cells betray their nervous disposition.

Authors:  Elizabeth J Meredith; Anita Chamba; Michelle J Holder; Nicholas M Barnes; John Gordon
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.